Pursuant to Regulation 34(1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 ("Listing Regulations") enclosed please find the a copy of the Annual Report ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics Ltd has submitted its Annual Report for FY 2024-25 along with the Notice of the 43rd Annual General Meeting, scheduled for August 21, 2025 via video conferencing. The AGM agenda includes adoption of audited standalone and consolidated financial statements, re-appointment of Mr. Cedric Lobo (Executive Director) who retires by rotation, and approval to revise the related party transaction limit with subsidiary Lensco – The Lens Company from Rs. 9.00 Crores to Rs. 12.00 Crores for FY 2025-26 due to growing demand from US markets. Other items include approval of material RPTs for FY 2026-27, appointment of Ms. Girija Nagvekar as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30), and approval for Mr. Gaurav Gupta (relative of Chairman K.G. Gupta) to draw USD 7,400/month remuneration as CEO of subsidiary Lensco. The company is also seeking fresh shareholder approval for a borrowing limit of Rs. 50 Crores under Section 180(1)(c) and the ability to create charges on its assets. The company has not declared any dividend since FY 2010-11.
Routine compliance filing with AGM business items. The 33% increase in RPT limit with Lensco (Rs. 9 Cr → Rs. 12 Cr) signals expected higher business volumes with the US-focused subsidiary. Borrowing limit of Rs. 50 Crores is being renewed but no major capital raise is announced. Long-standing absence of dividends (since FY11) continues.